PROTHENA CORPORATION PUBLIC LIMITED COMPANY (PRTA)

Prothena Corporation plc (PRTA) Stock Analysis: A Biotechnology Pioneer with 154% Potential Upside

DUBLIN--(BUSINESS WIRE)--$PRTA #Prothena--Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company with a robust pipeline of investigational therapeutics built on protein dysregulation expertise, today announced that it will report its second quarter and first six ...

Anne Evans Kingston, the Chief Strategy Officer of $PRTA, sold 7,662 shares of the company on 07-29-2026 for an estimated $64,919. We received data on the trade from a recent SEC filing. This was a sale of approximately 12.1% of their shares of this class of stock.

Chief Strategy Officer Anne Evans Kingston sold 7,662 Prothena shares at $8.47 and had 3,498 shares withheld at $8.56 to cover tax obligations, including a Rule 10b5-1 plan trade.

The biotech will also report its first six months of 2026 results after U.S. markets close, with no conference call scheduled alongside the release.